Enzyme News and Research

RSS

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

Diamedix files a 510(k) premarket submission with the FDA for its Mago4S assay system

IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration (“FDA”) for its next -generation fully automated Enzyme-linked Immunosorbent Assay (“ELISA”) system for autoimmune and infectious disease testing, named the Mago®4S.

1 Oct 2009

OICR completes evaluation of NEB's new reagents for use with the Illumina Genome Analyzer

Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II.

From New England Biolabs 1 Oct 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Amicus Therapeutics to initiate Phase 1 study of AT2220

Amicus Therapeutics today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease.

30 Sep 2009

Critical biochemical pathways linked to the aging of human muscle identified

A study led by researchers at the University of California, Berkeley, has identified critical biochemical pathways linked to the aging of human muscle. By manipulating these pathways, the researchers were able to turn back the clock on old human muscle, restoring its ability to repair and rebuild itself.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Metabolic syndrome related to elevated levels of liver enzymes in obese teenagers

Researchers studying a large sample of adolescent American boys have found an association between metabolic syndrome, which is a complication of obesity, and elevated liver enzymes that mark potentially serious liver disease.

30 Sep 2009

Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex

Repros Therapeutics today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex.

29 Sep 2009

U.S. PTO to reexamine the patents in Cellectis-Precision BioSciences litigation

Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605 (the ‘605 patent), which Cellectis SA (Alternext: ALCLS) has asserted against Precision in litigation.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

UK scientists discover new route by which leukaemia develops

CANCER RESEARCH UK SCIENTISTS have discovered a completely new route by which leukaemia develops, according to research published in Nature.

28 Sep 2009

Researchers discover potential treatment for Friedreich's ataxia

Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials, which will be a welcome event for disease sufferers who currently have few treatment options.

25 Sep 2009

Central metabolic network model of Thermotoga maritima bacterium developed

Investigators at Burnham Institute for Medical Research (Burnham), University of California, San Diego (UC San Diego), The Scripps Research Institute (TSRI), Genomics Institute of the Novartis Research Foundation (GNF) and other institutions have constructed a complete model, including three dimensional protein structures, of the central metabolic network of the bacterium Thermotoga maritima (T. maritima).

25 Sep 2009

Senior chemist receives nation's highest award for achievement in science

Joanna Fowler, a senior chemist and Director of the Radiotracer Chemistry, Instrumentation and Biological Imaging Program at the U.S. Department of Energy's Brookhaven National Laboratory, will be awarded the National Medal of Science at a White House ceremony on October 7. She is one of nine researchers named by President Barack Obama to receive the nation's highest award for lifetime achievement in science.

25 Sep 2009

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries - both of which increase the risk of heart disease.

25 Sep 2009

NIH awards three UNC Scientists for high risk and innovative research

Three scientists from the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center have received prestigious awards from the National Institutes of Health (NIH) aimed at encouraging "high risk" and innovative research.

24 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Acetaminophen can prevent age-related problems

Recent studies conducted by Dr. Eric Blough and his colleagues at Marshall University have shown that use of the common pain reliever acetaminophen may help prevent age-associated muscle loss and other conditions.

24 Sep 2009

Enzyme News and Research

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Diamedix files a 510(k) premarket submission with the FDA for its Mago4S assay system

OICR completes evaluation of NEB's new reagents for use with the Illumina Genome Analyzer

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Amicus Therapeutics to initiate Phase 1 study of AT2220

Critical biochemical pathways linked to the aging of human muscle identified

Genetic factors play an important role in the development of type 1 diabetes

Metabolic syndrome related to elevated levels of liver enzymes in obese teenagers

Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex

U.S. PTO to reexamine the patents in Cellectis-Precision BioSciences litigation

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

UK scientists discover new route by which leukaemia develops

Researchers discover potential treatment for Friedreich's ataxia

Central metabolic network model of Thermotoga maritima bacterium developed

Senior chemist receives nation's highest award for achievement in science

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

NIH awards three UNC Scientists for high risk and innovative research

New method found for the treatment of pancreatic cancer

Acetaminophen can prevent age-related problems

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo